Incyte Corporation

This early-phase study tests a new drug, INCB040093, alone or with another drug (itacitinib) in 121 adults with B-cell blood cancers that have come back or not responded to prior treatment. The main goal is to find safe doses and check for side effects. Researchers will also look…

This early-stage study tests an experimental drug called INCB000928, given alone or with a standard medicine (ruxolitinib), for people with myelofibrosis who have low red blood cells (anemia) and need frequent blood transfusions. The goal is to see if the drug is safe and can rai…

This study offers continued access to the drug parsaclisib (alone or with other medicines) for people with B-cell cancers who were already benefiting from it in earlier Incyte studies. About 112 participants will receive the treatment and be monitored for side effects. The goal i…

This study tests an experimental drug called INCB099280 in 63 adults with advanced squamous cell skin cancer that cannot be removed by surgery or radiation. The main goals are to see if the drug is safe and whether it shrinks tumors. Participants take the drug and are monitored f…

This phase 3 study tests whether adding the drug INCMGA00012 to standard platinum chemotherapy helps people with advanced non-small cell lung cancer live longer. About 583 participants who have not had prior treatment for metastatic disease will receive either chemo plus the new …

This early-stage study tests a new drug called INCB057643, given alone or with an existing drug (ruxolitinib), for people with myelofibrosis and other advanced blood cancers. The main goal is to check safety and see if the drug can shrink an enlarged spleen, a common problem in t…

This study is for adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants receive a modified dosing schedule of two drugs, tafasitamab and lenalidomide, to see if it is safe and how the body pro…

This study tests a daily pill called povorcitinib for adults with nonsegmental vitiligo, a condition where the skin loses color in patches. Researchers want to see if the drug can safely improve skin color on the face and body over 52 weeks. About 467 participants are taking eith…

This study tests an experimental drug called povorcitinib for people with prurigo nodularis, a condition causing intense itching and hard bumps on the skin. About 346 adults aged 18 to 75 will receive either the drug or a placebo to see if it reduces itch and clears lesions over …